These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23486868)

  • 1. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
    Matthews L; Marasco R; Jenkinson M; Küker W; Luppe S; Leite MI; Giorgio A; De Stefano N; Robertson N; Johansen-Berg H; Evangelou N; Palace J
    Neurology; 2013 Apr; 80(14):1330-7. PubMed ID: 23486868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
    Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.
    Bensi C; Marrodan M; González A; Chertcoff A; Osa Sanz E; Chaves H; Schteinschnaider A; Correale J; Farez MF
    Mult Scler Relat Disord; 2018 Oct; 25():246-250. PubMed ID: 30144694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain lesion distribution criteria distinguish demyelinating diseases in China.
    Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.
    Liao MF; Chang KH; Lyu RK; Huang CC; Chang HS; Wu YR; Chen CM; Chu CC; Kuo HC; Ro LS
    BMC Neurol; 2014 Nov; 14():218. PubMed ID: 25433369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    Huh SY; Min JH; Kim W; Kim SH; Kim HJ; Kim BJ; Kim BJ; Lee KH
    Mult Scler; 2014 May; 20(6):695-704. PubMed ID: 24072726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach.
    Ota M; Sato N; Okamoto T; Noda T; Araki M; Yamamura T; Kunugi H
    Mult Scler Relat Disord; 2015 Nov; 4(6):515-20. PubMed ID: 26590657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
    Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
    Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
    Hyun JW; Huh SY; Shin HJ; Woodhall M; Kim SH; Irani SR; Lee SH; Waters P; Kim HJ
    Mult Scler; 2019 Apr; 25(4):585-590. PubMed ID: 29512413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain and spinal MRI features distinguishing MS from different AQP4 antibody serostatus NMOSD at disease onset in a cohort of Latin American patients.
    Carnero Contentti E; Marques VD; Soto de Castillo I; Tkachuk V; Barreira AA; Caride A; Castillo MC; Cristiano E; de Aquino Cruz C; Braga Diégues Serva G; Santos ACD; Labarca R; Lavigne Moreira C; López PA; Miguez J; Molina O; Pettinicchi JP; Rojas JI
    Mult Scler; 2020 Jul; 26(8):945-954. PubMed ID: 31124748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
    Cai MT; Zheng Y; Shen CH; Yang F; Fang W; Zhang YX; Ding MP
    Mult Scler; 2021 May; 27(6):871-882. PubMed ID: 32672091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.
    Keller A; Leidinger P; Meese E; Haas J; Backes C; Rasche L; Behrens JR; Pfuhl C; Wakonig K; Gieß RM; Jarius S; Meder B; Bellmann-Strobl J; Paul F; Pache FC; Ruprecht K
    J Neuroinflammation; 2015 Oct; 12():196. PubMed ID: 26521232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
    Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.